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Summary
Background.  —  Hypertrophic  cardiomyopathy  (HCM)  causes  various  degrees  of  ﬁbrosis  resulting
in left  ventricular  function  impairment,  which  can  be  measured  using  mitral  annular  plane
systolic excursion  (MAPSE).
Aims.  —  To  determine  the  values  for  septal,  lateral  and  average  MAPSE  using  cardiovascular
magnetic resonance  (CMR)  in  healthy  controls  and  patients  with  HCM;  and  to  investigate  whether
MAPSE correlated  with  the  extent  of  ﬁbrosis.
Methods.  —  Patients  with  HCM  and  healthy  controls  underwent  CMR.
Results.  —  In  50  healthy  controls,  septal  and  lateral  MAPSE  were  comparable  and  showed  excel-
lent intra-  and  inter-observer  reliability.  Patients  with  HCM  had  signiﬁcantly  reduced  septal,
lateral and  average  MAPSE  compared  to  healthy  controls.  Furthermore,  in  patients  with  HCM,
septal MAPSE  measurements  were  signiﬁcantly  reduced  compared  to  lateral  ones.  Correspond-
ingly, the  septal  myocardial  segments  showed  signiﬁcantly  more  late  gadolinium  enhancement
(LGE) than  lateral  ones.  No  signiﬁcant  differences  were  found  between  echocardiographic  and
CMR MAPSE  measurements  in  healthy  controls  and  patients  with  HCM.  Patients  who  suffered  a
major adverse  cardiac  event  or  stroke  revealed  a  signiﬁcantly  reduced  MAPSE  and  a  signiﬁcantly
greater  LGE  extent  compared  to  event-free  patients  with  HCM.
Conclusions.  —  MAPSE  measurement  using  CMR  is  feasible,  reproducible  and  comparable  to
echocardiography  in  healthy  controls  and  patients  with  HCM.  The  asymmetric  and  mainly  sep-
tal distribution  of  myocardial  hypertrophy  and  ﬁbrosis  detected  by  LGE  in  patients  with  HCM
was reﬂected  by  signiﬁcantly  reduced  septal  versus  lateral  MAPSE.  Therefore,  reduced  MAPSE
seems to  be  an  easily  determinable  marker  of  ﬁbrosis  accumulation  leading  to  left  ventricular
mechanical  dysfunction  and  also  seems  to  have  a  prognostic  implication.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  — La  cardiomyopathie  hypertrophique  (CMH)  est  une  maladie  d’origine  génétique.
L’ampleur  des  cicatrices  myocardiques  est  variable  et  affecte  la  fonction  systolique  et  dias-
tolique du  ventricule  gauche  de  ces  patients.  L’excursion  systolique  dans  le  plan  de  l’anneau
mitral (MAPSE)  représente  une  mesure  rapide  et  simple  qui  traduit  le  raccourcissement  longi-
tudinal du  ventricule  gauche  et  donne  également  des  informations  sur  la  fonction  diastolique.
Objectif.  —  Le  but  de  cette  étude  était  d’établir  des  valeurs  de  références  pour  la  mesure
du MAPSE  à  l’anneau  mitral  septal  (MAPSE  septal)  et  à  l’anneau  mitral  latéral  (MAPSE  latéral)
ainsi que  la  moyenne  des  deux  mesures  (MAPSE  moyen)  en  utilisant  l’imagerie  par  résonance
magnétique  (IRM)  sur  des  sujets  contrôle  sains.  Nous  avons  comparés  les  mesures  de  MAPSE  des
sujets contrôle  avec  ceux  de  patients  porteurs  d’une  CMH.  De  plus,  nous  avons  corrélé  le  MAPSE
avec l’ampleur  des  cicatrices  myocardiques.
Méthodes.  —  Exploration  par  IRM  sur  88  patients  porteurs  d’une  CMH  et  50  sujets  contrôle  sains.
Résultats.  —  Les  MAPSE  septal  et  latéral  ont  été  comparables  et  présentaient  une  excellente
ﬁabilité intra-  et  interobservateur  dans  le  groupe  contrôle  sain.  De  plus,  les  mesures  de  MAPSE
ne montraient  pas  de  différence  signiﬁcative  entre  échocardiographie  et  IRM  chez  les  porteurs
d’une CMH  et  les  sujets  contrôle  sains.  Les  patients  porteurs  d’une  CMH  montraient  une  consi-
dérable réduction  des  mesures  de  MAPSE  septal,  latéral  et  moyen  comparés  aux  sujets  sains.  De
plus, la  mesure  du  MAPSE  septal  était  considérablement  diminuée  en  comparaison  de  celle  du
MAPSE latéral  chez  les  patients  porteurs  d’une  CMH.  De  plus,  les  segments  myocardiques  septaux
montraient  plus  de  cicatrices  myocardiques  comparés  aux  segments  myocardiques  latéraux.
Les porteurs  d’une  CMH  souffrant  d’un  événement  adverse  majeur  (mort  ou  greffe  cardiaque,
tachycardie  ventriculaire)  ou  d’une  attaque  apoplexie  montraient  des  mesures  de  MAPSE  consi-
dérablement  diminuées  ainsi  qu’un  rehaussement  tardive  plus  étendu  comparé  aux  porteurs
d’une CMH  sans  événements.
Conclusions.  — La  mesure  du  MAPSE  par  l’utilisation  de  l’IRM  est  faisable,  ﬁable  et  comparable
à celle  de  l’échocardiographie  sur  des  sujets  sains  ainsi  que  sur  les  porteurs  d’une  CMH.
358  C.  Doesch  et  al.
La  distribution  septale  de  l’hypertrophie  et  des  plages  de  rehaussement  tardif  a  été  identiﬁée
par une  considérable  diminution  des  mesures  du  MAPSE  septal  par  rapport  au  MAPSE  latéral.  Une
diminution  du  MAPSE  pourrait  donc  représenter  une  mesure  simple  pour  identiﬁer  les  cicatrices
myocardiques  dans  la  CMH  et  semble  avoir  un  rôle  pronostique  défavorable.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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ypertrophic  cardiomyopathy  (HCM)  is  a  complex  form  of
enetic  heart  disease.  Macroscopically,  HCM  is  characterized
y  marked,  frequently  asymmetrical  left  ventricular  hyper-
rophy  in  the  absence  of  other  causes,  such  as  hypertension
r  valve  disease.  Histopathologically,  it  is  associated  with
ardiomyocyte  and  cardiac  hypertrophy,  myocyte  disarray,
nterstitial  and  replacement  ﬁbrosis,  and  dysplastic  intramy-
cardial  arterioles,  which  are  all  thought  to  interfere  with
yocardial  force  generation  and  relaxation  [1,2].  Late
adolinium  enhancement  (LGE)  cardiovascular  magnetic
esonance  (CMR)  imaging  is  able  to  visualize  myocardial
brosis  [3,4]  associated  with  left  ventricular  systolic  and
iastolic  dysfunction.
Mitral  annular  plane  systolic  excursion  (MAPSE)  can  eas-
ly  be  assessed  echocardiographically  and  correlates  with
ystolic  longitudinal  ventricular  systolic  function,  parame-
ers  of  diastolic  function  (such  as  early  diastolic  ﬁlling/early
iastolic  mitral  annular  velocity  [E/E′]  and  mitral  ﬂow  prop-
gation  velocity)  as  well  as  left  ventricular  twist  and  torsion
5].  MAPSE  can  be  determined  either  on  the  lateral  [6,7]  or
eptal  annular  site  [8]  or  is  given  as  the  average  between
he  measurements  at  the  septal  and  lateral  annular  site  [5].
In  HCM,  regions  most  affected  by  the  hypertrophic
rocess  are  the  septum  and  the  base  [9].  Furthermore,
yocardial  ﬁbrosis  is  known  to  be  most  pronounced  at  the
unction  of  the  septum  and  the  left  ventricular  and  right
entricular  free  wall  where  myoﬁbrillar  disarray  is  maximal
10].  Therefore,  we  assumed  that  the  septal  MAPSE  would
e  most  affected.
To date,  there  are  no  data  available  on  MAPSE  measure-
ents  using  state  of  the  art  CMR,  and  cut-off  values  are
erived  from  echocardiography.  Thus,  the  primary  aim  of
ur  study  was  to  determine  the  values  for  septal,  lateral  and
verage  MAPSE  in  healthy  controls  using  CMR.  Secondly,  we
etermined  these  values  in  patients  with  HCM  and  compared
hem  among  patient  subgroups  and  to  healthy  controls.
hirdly,  we  investigated  whether  MAPSE  correlated  with  the
xtent  of  ﬁbrosis.
ethods
tudy population
onsecutive  patients  with  HCM  referred  for  CMR  were
nrolled  between  January  2004  and  December  2012  at  our
ospital.  The  population  included  45  patients  as  reported
arlier  [11].  All  patients  with  HCM  were  diagnosed  based  on
onventional  criteria:  left  ventricular  hypertrophy  ≥  15  mm
n  two-dimensional  echocardiography  in  the  absence  of
r
v
enother  disease  that  could  account  for  the  hypertrophy  [12].
ypertrophic  non-obstructive  cardiomyopathy  (HNCM)  was
eﬁned  as  a pressure  gradient  ≤  30  mmHg  at  rest  and  after
rovocation.  Patients  with  a  pressure  gradient  >  30  mmHg  at
est  or  after  provocation  were  classiﬁed  as  having  hyper-
rophic  obstructive  cardiomyopathy  (HOCM).
Age-  and  sex-matched  healthy  subjects  served  as  con-
rols  and  satisﬁed  the  following  criteria:  normal  physical
xamination,  normal  blood  pressure  (<  130/85  mmHg),  nor-
al  electrocardiographic  ﬁndings,  no  history  of  chest  pain  or
yspnoea,  no  diabetes,  no  hyperlipidaemia  and  normal  two-
imensional  echocardiography  and  Doppler  examination.
one  of  the  control  subjects  was  on  medication.  Exclusion
riteria  for  healthy  controls  were:  the  presence  of  signs
r  symptoms  of  cardiac  diseases,  hypertension  or  diabetes;
moking;  or  participation  in  competitive  sports.
The  study  design  complied  with  the  declaration  of
elsinki  and  was  approved  by  local  ethical  committee,  Medi-
al  Ethic  Commission  II,  Faculty  of  Medicine  Mannheim,
niversity  of  Heidelberg,  Germany.  Written  informed  con-
ent  was  obtained  from  all  participants  and  data  were
nalysed  anonymously.
MR image acquisition
ll  studies  were  performed  using  a  1.5-Tesla  whole  body
maging  system  (Magnetom  Avanto  and  Sonata,  Siemens
edical  Systems,  Healthcare  Sector,  Erlangen,  Germany)
sing  a  four-element  (Sonata)  or  six-element  (Avanto)
hased-array  body  coil.
Cine  images  were  acquired  using  a  retrospective
lectrocardiographic-gated,  balanced  segmented  steady
tate  free  precession  (trueFISP)  sequence  in  three  long-
xis  views  (2-,  3-,  and  4-chamber  views)  and  in  multiple
hort-axis  views,  covering  the  entire  left  ventricle  from
ase  to  apex.  LGE  images  were  obtained  10—15  minutes
fter  intravenous  administration  of  0.2  mmol/kg  gadoteric
cid  (Dotarem,  Guerbet,  Roissy  CdG  Cedex,  France),  using
n  inversion  recovery  turbo  Fast  Low  Angle  Shot  sequence
t  the  same  position  as  the  long-  and  short-axis  cine
cquisitions  in  end-diastole  [13]. The  inversion  time  was
djusted  by  patient  to  optimally  null  the  signal  from  normal
yocardium,  typically  250—300  ms.
MR image analysis
eft  ventricular  mass  and  volumes  [14]  as  well  as  right  ven-
ricular  [15]  and  left  atrial  volumes  [16]  were  determined
sing  CMR  as  previously  described.  The  left  ventricular
emodelling  index  (LVRI)  was  determined  as  the  ratio  of  left
entricular  end-diastolic  mass  (LV-EDM)  to  left  ventricular
nd-diastolic  volume  (LV-EDV)  [17].  MAPSE  measurements
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Figure 1. Mitral annular plane systolic excursion (MAPSE) using cardiovascular magnetic resonance (CMR) was measured on the four-
chamber cine image at (A) end-diastole and (B) end-systole. Comparable to echocardiography, two separate reference lines were drawn
in diastole and systole from the basal septal (septal MAPSE) and lateral side of the atrioventricular plane (lateral MAPSE) to a reference
point outside the left ventricular (LV) apex. The point outside the left ventricular apex was chosen in extension to the left ventricular apex
and had to stay unchanged at end-diastole and end-systole. In order to ensure that the reference point outside the left ventricular apex
stayed unchanged during end-systole, we left the curser at the point of the chosen reference point while scrolling from end-diastole to end-
systole. Septal and lateral MAPSE as indicated by the red lines in B were deﬁned as the difference between septal or lateral left ventricular
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were  assessed  on  four-chamber  view  cine  images.  The
distance  between  the  basal  septal  mitral  annulus  (septal
MAPSE),  the  basal  lateral  mitral  annulus  (lateral  MAPSE)
and  a  reference  point  outside  the  left  ventricular  apex
was  measured  in  end-diastole  and  end-systole.  The  distance
travelled  by  the  septal  and  lateral  annulus  from  end-diastole
to  end-systole  was  calculated  as  septal  and  lateral  MAPSE  by
subtracting  the  left  ventricular  end-systolic  length  (LVESL)
from  the  left  ventricular  end-diastolic  length  (LVEDL)  as
shown  on  Fig.  1.  Average  MAPSE  was  calculated  as  the  aver-
age  of  septal  and  lateral  MAPSEs.
LGE quantiﬁcation
The  extent  of  LGE  was  quantiﬁed  visually  using  the  standard
left  ventricular  17-segment  model  [18].  Each  segment  was
visually  scored  for  the  total  extent  of  LGE  as  previously
described  [19].  The  17  segments  were  grouped  into  four
cardiac  regions:
• anterior  region,  including  segments  1,  7,  13  and  17;
• septal  region,  including  segments  2,  3,  8,  9,  14  and  17;
• posterior  region,  including  segments  4,  10,  15  and  17;
• lateral  region,  including  segments  5,  6,  11,  12,  16  and  17.
To  determine  the  LGE  extent  in  the  septal  and  lateral
regions,  the  scores  of  these  segments  were  summed.  The
resulting  septal  and  lateral  LGE  extents  were  then  expressed
as  a  percentage  of  the  maximum  possible  score  of  24.
Echocardiography
In  20  randomly  selected  HCM  patients,  a  retrospective  analy-
sis  of  the  transthoracic  echocardiograms  (TTEs)  obtained  for
clinical  indications  at  the  time  of  CMR  examination  using  a
commercially  available  ultrasound  system  (Vivid  7  or  Vivid  i,
GE  Ultrasound,  Horten,  Norway  with  a  2.5  MHz  phased-array
d
w
r
l left ventricular end-systolic length (LVESLseptal or LVESLlateral) (B),
ransducer)  was  performed.  Additionally,  a  TTE  analysis  was
erformed  in  the  ﬁrst  20  healthy  controls  using  the  same
ltrasound  system.  Standard  echocardiographic  images  were
btained  at  end-expiratory  apnoea.  M-mode  echocardiog-
aphy  through  the  mitral  valve  annulus,  from  the  apical
our-chamber  view  at  both  the  septal  and  lateral  annuli,
as  performed.  The  images  were  optimized  for  routine  four-
hamber  view  evaluation.  The  M-line  was  positioned  through
he  medial  and  lateral  annulus  and  included  the  tissue-blood
order  for  easy  identiﬁcation  of  the  motion  of  the  annulus.
he  trough  of  the  motion  was  deﬁned  as  the  end-diastolic
osition  of  the  annulus,  measured  at  the  tip  of  the  QRS  com-
lex.  The  peak  was  deﬁned  as  the  maximal  systolic  excursion
oint.  All  images  were  stored  digitally  and  analysed  ofﬂine
y  a single  investigator  blinded  to  CMR  data  using  EchoPAC,
E  Ultrasound.
ollow-up data and deﬁnition of  study
ndpoints
ong-term  follow-up  was  performed  retrospectively  by  tele-
hone  contact.  Reported  clinical  events  were  conﬁrmed  by
eview  of  the  corresponding  medical  records  in  our  elec-
ronic  Hospital  Information  System  or  contact  with  the
eneral  practitioner,  referring  cardiologist  or  the  treating
ospital.  The  observer  was  unaware  of  the  CMR  results  and
ollected  data  with  a  standardized  questionnaire.  The  def-
nition  of  major  adverse  cardiac  event  (MACE)  required  the
ocumentation  of  cardiac  death,  heart  transplantation  or
igniﬁcant  ventricular  arrhythmia.  In  case  of  out-of-hospital
eath  not  followed  by  autopsy,  sudden  unexpected  death
as  classiﬁed  as  cardiac  death.  Stroke  was  deﬁned  as  neu-
ological  impairment  and  disability  due  to  vascular  causes
asting  longer  than  24  hours.  Patients  who  had  a  stroke  and
3 C.  Doesch  et  al.
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Table  1  Patient  demographics  and  baseline
characteristics.
All  patients  with  HCM
(n  =  88)
Age  (years)  56  ±  13
Men  58  (65.9)
HCM
HOCM  37  (42.0)
HNCM  51  (58.0)
Morphological  features
Asymmetrical  septal
hypertrophy
76  (86.4)
Symmetrical  hypertrophy  8  (9.1)
Apical  hypertrophy  3  (3.4)
Midventricular  hypertrophy  1  (1.1)
HCM: hypertrophic cardiomyopathy; HNCM: hypertrophic non-
obstructive cardiomyopathy; HOCM: hypertrophic obstructive
cardiomyopathy. Data are mean ± standard deviation or number
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uffered  from  a  MACE  over  the  course  of  follow-up  were  only
ounted  regarding  MACE.
tatistical analysis
ata  are  presented  as  mean  ±  standard  deviation  (with  or
ithout  ranges)  or  counts  and  percentages.  Continuous
arameters  were  compared  using  a  two-tailed  student’s  t-
est.  Pearson’s  correlation  was  used  to  correlate  septal,
ateral  and  average  MAPSE  to  the  extent  of  LGE  and  to  cor-
elate  the  extent  of  LGE  in  septal  regions  to  septal  MAPSE
nd  the  extent  of  LGE  in  lateral  regions  to  lateral  MAPSE.
The  level  of  agreement  among  the  MAPSE  measure-
ents  using  CMR  in  healthy  controls  was  evaluated  using
land—Altman  analysis  [20].  Intra-  and  inter-observer  vari-
bilities  were  assessed  and  expressed  as  mean  difference
etween  two  measurements  (d  =  bias),  the  standard  devi-
tion  (SD)  of  the  differences,  the  limits  of  agreement
d  ±  1.96  ×  SD)  and  the  coefﬁcient  of  variation  (CV  =  2  ×  SD)
20].
For  septal,  lateral  and  average  MAPSE  measurements,
sing  either  echocardiography  or  CMR,  the  interstudy  reli-
bility  was  assessed  using  Lin’s  concordance  correlation
oefﬁcient  (CCC)  in  20  randomly  selected  healthy  controls  as
ell  as  20  randomly  selected  patients  with  HCM  [21].  A  CCC
alue  of  1  indicates  perfect  agreement;  values  <  0.5  were
onsidered  to  be  poor  agreement;  values  between  0.5  and
.7  to  be  moderate  agreement;  and  values  >  0.7  to  be  good
o  excellent  agreement.
All  results  were  considered  statistically  signiﬁcant  when
 <  0.05.  Analyses  were  performed  with  Statistical  1  Package
or  Social  Sciences  (SPSS  for  windows  14.0,  Chicago,  IL,
SA).
esults
 total  of  103  patients  with  HCM  were  enrolled  during
004—2012.  Fifteen  patients  were  excluded,  due  to  incom-
lete  clinical  or  CMR  data  (n  =  10)  or  insufﬁcient  CMR  image
uality  (n  =  2  due  to  tachyarrhythmias,  n  =  3  due  to  difﬁ-
ulties  in  the  angulation  when  planning  the  four-chamber
iew),  yielding  a  total  number  of  88  patients  ﬁnally  included
n  this  study.  Baseline  patient  demographics  and  character-
stics  are  presented  in  Table  1.  Fifty  age-  and  sex-matched
ealthy  subjects  served  as  controls.
The  CMR  characteristics  of  patients  with  HCM  and  healthy
ontrols  are  summarized  in  Table  2.  In  healthy  controls,
eptal  and  lateral  MAPSE  were  comparable  (1.28  ±  0.38  cm
s.  1.38  ±  0.40  cm;  P  =  0.3).  Normal  values  for  septal,  lat-
ral  and  average  MAPSE  were  all  approximately  0.9—2.5  cm
Table  2).  In  50  healthy  controls,  CMR-derived  MAPSE  mea-
urements  showed  an  excellent  reproducibility.  Intra-  and
nter-observer  variability  for  all  MAPSE  measurements  was
ow,  as  indicated  by  the  small  biases  (d)  and  low  CVs  for
ach  measurement  (Table  3).
In  all  patients  with  HCM,  septal,  lateral  and  aver-
ge  MAPSE  were  all  signiﬁcantly  reduced  compared  to
ealthy  controls  (Table  2).  In  all  patients  with  HCM,  septal
APSE  was  signiﬁcantly  reduced  compared  to  lateral  MAPSE
P  =  0.01).
e
o
H
l(%).
In  all  patients  with  HCM,  there  was  a  moderate  linear
nverse  relationship  between  LGE  extent  and  reduced  sep-
al  MAPSE  (r  =  0.34;  P  =  0.0015),  average  MAPSE  (r  =  0.35;
 =  0.001)  and  lateral  MAPSE  (r  =  0.34;  P  =  0.0015).  Compar-
ng  the  LGE  extent  in  septal  and  lateral  myocardial  segments
evealed  a signiﬁcantly  elevated  septal  LGE  extent  (15  ±  18%
s.  6  ±  10%;  P  =  0.0001).  The  signiﬁcantly  increased  septal
GE  extent  (15  ±  18%)  was  associated  with  a  signiﬁcantly
educed  septal  MAPSE  (0.93  ±  0.33  cm).  Comparing  septal
GE  extent  to  septal  MAPSE  revealed  a  weak  linear  relation-
hip  (r  =  0.21;  P  =  0.06).  In  contrast,  the  lower  LGE  extent
n  lateral  myocardial  segments  (6  ±  10%)  resulted  in  a  lesser
eduction  of  lateral  MAPSE  (1.08  ±  0.37  cm).  Nevertheless,
he  relationship  between  the  lateral  LGE  extent  and  reduced
ateral  MAPSE  was  signiﬁcant  (r  =  0.26;  P  =  0.02).
Looking  at  the  subgroup  of  37  patients  with  HOCM
Table  4)  revealed  that  septal  MAPSE  (0.92  ±  0.37  cm)
as  signiﬁcantly  reduced  compared  to  lateral  MAPSE
1.10  ±  0.36  cm;  P  =  0.04).  In  patients  with  HOCM,  as  in  the
hole  group  of  patients,  the  septal  segments  exhibited  a  sig-
iﬁcantly  greater  LGE  extent  compared  to  the  lateral  ones
11  ±  18%  vs.  2  ±  6%;  P  =  0.01)  accompanied  by  a  septally
ccentuated  reduction  of  MAPSE.
The  same  relation  between  septal  and  lateral  MAPSE  was
bserved  in  all  57  patients  with  HCM  and  LGE  (Table  4)
ho  also  revealed  a  signiﬁcantly  lower  septal  MAPSE
0.90  ±  0.33  cm)  compared  to  lateral  MAPSE  (1.06  ±  0.39  cm;
 =  0.02).  In  these  patients,  septal  myocardial  segments  also
isplayed  more  LGE  extent  than  the  lateral  ones  (24  ±  18%
s.  12  ±  14%;  P  <  0.0001),  along  with  a more  marked  reduc-
ion  of  septal  MAPSE.  In  contrast,  septal  (0.90  ±  0.32  cm)  and
ateral  MAPSE  (0.99  ±  0.35  cm;  P  =  0.2)  were  comparable  in
1  patients  with  HNCM  (Table  4).  Looking  at  the  total  LGE
xtents,  patients  with  HNCM  revealed  the  largest  amount
f  LGE.  As  opposed  to  the  other  subgroups,  in  patients  with
NCM,  the  distribution  of  LGE  extent  in  septal  (17  ±  17%)  and
ateral  myocardial  segments  (11  ±  14%;  P  =  0.07)  was  similar,
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Table  2  CMR  characteristics  of  patients  with  HCM  and  healthy  controls.
All  patients  with  HCM(n =  88)  Healthy  controls(n  =  50)  P
LVEF  (%)  61  ±  10  (29—85)  60  ±  4  (55—67)  0.86
LV-EDVI  (mL/m2)a 77  ±  21  (28—143)  76  ±  12  (51—106)  0.88
LV-ESVI  (mL/m2)a 32  ±  16  (10—96)  31  ±  5  (21—38)  0.83
LV-SVI  (mL/m2)a 45  ±  12  (14—88)  45  ±  10  (29—70)  0.97
LV-EDMI  (g/m2)a 98  ±  29  (51—182)  60  ±  11  (41—75)  <  0.001
LVRI  (g/mL)  1.34  ±  0.48  (0.73—3.84)  0.88  ±  0.27  (0.44—1.7)  <  0.001
LV  EDD  (mm) 52  ±  7  (36—68) 51  ±  5  (43—55) 0.61
SWT  (mm) 20  ±  5  (12—39) 9  ±  2  (5—11) <  0.001
PWT  (mm)  10  ±  3  (5—22)  9  ±  2  (5—10)  <  0.001
Indexed  LA  volume  (mL/m2)a 48  ±  21  (16—129)  23  ±  3  (20—29)  <  0.001
Septal  MAPSE  (cm)  0.93  ±  0.33  (0.15—1.82)  1.28  ±  0.38  (0.90—2.50)  <  0.001
Lateral  MAPSE  (cm)  1.08  ±  0.37  (0.36—2.07)  1.38  ±  0.40  (0.90—2.50)  0.001
Average  MAPSE  (cm)  1.00  ±  0.32  (0.29—1.74)  1.33  ±  0.38  (0.95—2.50)  <  0.001
Presence  of  LGE  57  (64.8)  —  —
Total  LGE  extent  (%)  13  ±  15  (0—63)  —  —
Septal  LGE  extent  (%)  15  ±  18  (0—71)  —  —
Lateral  LGE  extent  (%)  6  ±  10  (0—33)  —  —
CMR: cardiovascular magnetic resonance; EDD: end-diastolic dimension; EDMI: end-diastolic mass index; EDVI: end-diastolic volume
index; ESVI: end-systolic volume index; HCM: hypertrophic cardiomyopathy; LA: left atrial; LGE: late gadolinium enhancement; LV:
left ventricular; LVEF: left ventricular ejection fraction; LVRI: left ventricular remodelling index; MAPSE: mitral annular plane systolic
excursion; PWT: posterior wall thickness; SVI: stroke volume index; SWT: septal wall thickness. Data are mean ± standard deviation
(range) or number (%).
a Volumes are indexed to body surface area.
Table  3  Intra-  and  inter-observer  reliability  of  CMR-
derived  MAPSE  measurements.
Intra-observer
reliability
Inter-observer
reliability
Septal  MAPSE
d  ±  SD  0.00  ±  0.05  −0.03  ±  0.16
CV  0.1  0.3
LLA  to  ULA  −0.11  to  0.10  −0.35  to  0.29
Lateral  MAPSE
d  ±  SD  0.00  ±  0.08  0.00  ±  0.17
CV  0.2  0.3
LLA  to  ULA  −0.15  to  0.16  −0.34  to  0.34
Average  MAPSE
d  ±  SD  0.00  ±  0.05  −0.02  ±  0.12
CV  0.1  0.2
LLA  to  ULA  −0.09  to  0.09  −0.25  to  0.22
CMR: cardiovascular magnetic resonance; CV: coefﬁcient of
variation; d: bias = mean difference between two measure-
ments; LLA: lower limit of agreement = d − 1.96 × SD; MAPSE:
mitral annular plane systolic excursion; SD: standard deviation
of the difference between two measurements; ULA: upper limit
of agreement = d + 1.96 × SD.
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sesulting  in  an  analogous  reduction  of  septal  and  lateral
APSE.  The  analysis  of  reduction  in  septal  MAPSE  compared
o  lateral  MAPSE  in  all  patients  with  HCM,  patients  with
OCM,  patients  with  HNCM  and  patients  with  LGE,  as  well  as
he  extent  of  LGE  in  septal  compared  to  lateral  myocardial
egments  in  these  patients  is  visualized  on  Fig.  2.
In  31  patients  with  HCM,  no  LGE  was  detectable.  These
atients  also  presented  with  a  comparable  reduction  of  sep-
al  and  lateral  MAPSE  (0.99  ±  0.33  cm  vs.  1.11  ±  0.33  cm;
 =  0.2;  Table  4).
In  a  subgroup  analysis  of  20  healthy  controls  and  20
atients  with  HCM,  MAPSE  measurements  were  comparable
etween  echocardiography  and  CMR  (Table  5). The  inter-
tudy  reliability  for  the  measurement  of  septal  and  lateral
APSE  in  healthy  controls  and  patients  with  HCM  using
chocardiography  and  CMR  was  excellent  as  indicated  by
igh  CCCs  (0.94—0.99)  (Fig.  3).
During  a  follow-up  period  of  5.1  ±  3.3  years,  three
atients  (3.4%)  suffered  from  cardiac  death,  one  (1.1%)
nderwent  heart  transplantation  and  two  patients  (2.3%)
ith  an  implantable  cardioverter  deﬁbrillator  experi-
nced  shock  therapies  due  to  ventricular  arrhythmias.
ompared  to  patients  without  events,  those  suffer-
ng  from  a  MACE  presented  with  signiﬁcantly  reduced
eptal  (0.60  ±  0.18  vs.  0.96  ±  0.33  cm;  P  =  0.01),  lateral
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Table  4  CMR  characteristics  of  subgroups.
Patients
with  HOCM
(n  =  37)
Patients
with  HNCM
(n  =  51)
P  Patients  with
HCM  and  LGE
(n  =  57)
Patients  with  HCM
and  without  LGE
(n  =  31)
P
LVEF  (%)  63  ±  9  57  ±  12  0.02  59  ±  11  64  ±  8  0.02
LV-EDVI  (mL/m2)a 73  ±  17  80  ±  24  0.2  81  ±  21  68  ±  18  0.01
LV-ESVI  (mL/m2)a 28  ±  11  36  ±  21  0.05  35  ±  18  24  ±  10  0.005
LV-SVI  (mL/m2)a 44  ±  11  45  ±  13  0.8  47  ±  12  43  ±  13  0.2
LV-EDMI  (g/m2)a 103  ±  28 97  ±  33  0.4  101  ±  30  91  ±  27  0.1
LVRI  (g/mL) 1.49  ±  0.51 1.24  ±  0.39 0.02  1.30  ±  0.42  1.41  ±  0.59  0.3
LV  EDD  (mm)  50  ±  7  52  ±  7  0.3  53  ±  7  50  ±  8  0.07
SWT  (mm)  21  ±  5  19  ±  6  0.2  21  ±  5  17  ±  4  <  0.001
PWT  (mm)  11  ±  3  10  ±  3  0.4  10  ±  2  11  ±  3  0.2
Indexed  LA  volume  (mL/m2)  48  ±  23  49  ±  20  0.6  51  ±  24  43  ±  16  0.1
Septal  MAPSE  (cm)  0.92  ±  0.37  0.90  ±  0.32  0.9  0.90  ±  0.33  0.99  ±  0.33  0.2
Lateral  MAPSE  (cm)  1.10  ±  0.36  0.99  ±  0.35  0.3  1.06  ±  0.39  1.11  ±  0.33  0.6
Average  MAPSE  (cm) 1.01  ±  0.32  0.95  ±  0.31  0.6  0.97  ±  0.32  1.05  ±  0.30  0.3
Presence  of  LGE  18  (48.6)  39  (76.5)  0.01  57  (100)  0  (0)  —
Total  LGE  extent  (%) 19  ±  24 32  ±  28  0.03  20  ±  15  0  ±  0  —
Septal  LGE  extent  (%)  11  ±  18  17  ±  17  0.1  24  ±  18  0  ±  0  —
Lateral  LGE  extent  (%) 2 ±  6  11  ±  14  0.002  12  ±  14  0  ±  0  —
CMR: cardiovascular magnetic resonance; EDD: end-diastolic dimension; EDMI: end-diastolic mass index; EDVI: end-diastolic volume
index; ESVI: end-systolic volume index; HCM: hypertrophic cardiomyopathy; LA: left atrial; LGE: late gadolinium enhancement; LV:
left ventricular; LVEF: left ventricular ejection fraction; LVRI: left ventricular remodelling index; MAPSE: mitral annular plane systolic
excursion; PWT: posterior wall thickness; SVI: stroke volume index; SWT: septal wall thickness. Data are mean ± standard deviation or
number (%).
a Volumes are indexed to body surface area.
Table  5  MAPSE  measurements  by  echocardiography  or  CMR  in  a subgroup  analysis.
Healthy  controls  (n  =  20)  Patients  with  HCM  (n  =  20)
Echo  CMR  P  Echo  CMR  P
Septal  MAPSE  (cm)  1.44  ±  0.44  1.37  ±  0.42  0.6  0.96  ±  0.34  0.92  ±  0.33  0.7
Lateral  MAPSE  (cm) 1.47  ±  0.38  1.48  ±  0.43  0.97  0.98  ±  0.33  1.01  ±  0.33  0.7
CMR: cardiovascular magnetic resonance; HCM: hypertrophic cardiomyopathy; MAPSE: mitral annular plane systolic excursion. Data are
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0.77  ±  0.19  vs.  1.10  ±  0.37  cm;  P  =  0.04)  and  average  MAPSE
0.69  ±  0.19  vs.  1.02  ±  0.31  cm;  P  =  0.01)  as  well  as  a  signiﬁ-
antly  greater  amount  of  LGE  (58.8  ±  14.9%  vs.  23.7  ±  25.9%;
 =  0.002).  Ten  patients  (11.4%)  suffered  from  stroke  dur-
ng  follow-up.  The  occurrence  of  stroke  was  also  related
o  a  signiﬁcantly  reduced  septal  MAPSE  (0.73  ±  0.27  vs.
.96  ±  0.33  cm;  P  =  0.04)  as  well  as  a  signiﬁcantly  more  pro-
ounced  LGE  extent  (46.4  ±  28.9%  vs.  23.7  ±  25.9%;  P  =  0.01)
ompared  to  asymptomatic  patients.  Lateral  (0.92  ±  0.32
s.  1.10  ±  0.37  cm;  P  =  0.15)  and  average  MAPSE  (0.82  ±  0.27
s.  1.02  ±  0.31  cm;  P  =  0.06)  only  showed  a  trend  towards
t
s
t
oower  values  in  HCM  patients  with  stroke  compared  to  HCM
atients  without  events.
iscussion
o  the  best  of  or  knowledge,  the  present  study  is  the  ﬁrst
o  report  CMR-acquired  measurements  for  MAPSE  in  healthy
ubjects  and  in  patients  with  HCM.  Our  results  showed
hat  CMR-assessed  MAPSE  measurements  can  be  easily
btained  and  reveal  an  excellent  reproducibility  in  terms  of
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Figure 2. Interstudy agreement of mitral annular plane systolic excursion (MAPSE) measurements: scatterplots of (A, D) septal, (B, E)
lateral and (C, F) average MAPSE measurements in (A—C) 20 healthy controls and (D—F) 20 patients with hypertrophic cardiomyopathy (HCM)
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Cusing either echocardiography or cardiovascular magnetic resonan
correlation coefﬁcients (CCCs) and 95% conﬁdence intervals (CIs).
intra-  and  inter-observer  variability.  Furthermore,  we
provide  reference  values  for  MAPSE  measurements  in
healthy  controls  using  both  the  basal  septal  mitral  annulus
(septal  MAPSE)  and  the  basal  lateral  mitral  annulus  (lat-
eral  MAPSE).  The  values  for  septal  and  lateral  MAPSE  were
comparable  among  healthy  controls.  These  ﬁndings  are  in
line  with  a  previous  study  using  CMR  tagging  sequences  [22],
which  showed  comparable  values  for  septal  and  lateral  lon-
gitudinal  displacement  in  a  healthy  control  group.
In  routine  clinical  practice,  MAPSE  is  usually  measured
echocardiographically  on  the  lateral  annular  site.  In  the
current  literature,  to  date  there  is  no  consensus  on  the
best  site  to  measure  MAPSE  [5—8].  Using  CMR-derived
MAPSE  measurements,  we  obtained  a  slightly  better  intra-
and  inter-observer  reproducibility  compared  to  previous
echocardiography  studies  [23].  This  may  be  due  to  the  fact
that,  in  contrast  to  echocardiographical  measurements,  CMR
allows  the  free  choice  of  a  reference  point  outside  the  left
ventricular  apex  so  that  MAPSE  measurements  are  not  angle
dependent  and  therefore  more  robust.  Moreover,  a  subgroup
analysis  among  healthy  controls  as  well  as  patients  with  HCM
using  either  echocardiography  or  CMR  revealed  comparable
MAPSE  measurements.
Histopathologically,  HCM  is  characterized  by  cardiomy-
ocyte  and  cardiac  hypertrophy,  myocyte  disarray,  interstitial
and  replacement  ﬁbrosis  as  well  as  dysplastic  intramyocar-
dial  arterioles  [1,2].  These  histopathological  changes  result
in  a  diastolic  dysfunction  and,  later  in  the  disease  course,
i
a
t
aMR), shown with 45◦ lines of concordance and Lin’s concordance
ight  also  provoke  systolic  longitudinal  function  impair-
ent,  which  is  associated  with  poor  prognosis  [24,25].  In
atients  with  heart  failure,  MAPSE  correlated  with  param-
ters  of  systolic  longitudinal  and  diastolic  dysfunction  as
ell  as  with  left  ventricular  twist  and  torsion  [5].  There-
ore,  we  hypothesized  that  MAPSE  measurements  using
MR  might  also  be  altered  in  patients  with  HCM.  The
eft  ventricular  myocardial  region  of  the  conﬂuence  of
he  basal  anterior  and  inferior  septum  with  the  contigu-
us  anterior  free  wall  is  the  most  frequent  location  for
ncreased  wall  thickness  in  patients  with  HCM  [26].  Thus,
e  assumed  that  the  corresponding  septal  MAPSE  might  be
ost  affected.
As  expected,  our  ﬁndings  showed  signiﬁcantly  reduced
alues  for  all  MAPSE  measurements  in  patients  with  HCM
ompared  to  those  obtained  in  healthy  controls.  Contrary  to
ealthy  controls,  in  the  whole  group  of  patients  with  HCM,
s  well  as  in  patients  with  HOCM  and  in  all  HCM  patients
ith  LGE,  septal  MAPSE  was  signiﬁcantly  reduced  compared
o  lateral  MAPSE.  In  line  with  our  results,  Kramer  et  al.  [9]
nd  Young  et  al.  [22]  also  found  signiﬁcantly  reduced  val-
es  for  septal  compared  to  lateral  longitudinal  displacement
n  HCM  populations  in  contrast  to  healthy  subjects  using
MR  tagging.  At  that  time,  since  LGE  was  not  yet  available,
n  order  to  enable  an  in  vivo  tissue  characterization,  the
uthors  [9,22]  hypothesized  that  their  ﬁndings  may  be  due
o  a  more  pronounced  myocardial  disarray  in  the  septal  and
nteroseptal  region  than  in  the  lateral  wall.
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Figure 3. A. Reduction of septal and lateral mitral annular plane systolic excursion (MAPSE) in all patients with hypertrophic cardiomy-
opathy (HCM) as well as in the subgroups of patients with hypertrophic obstructive cardiomyopathy (HOCM), hypertrophic non-obstructive
cardiomyopathy (HNCM) and all patients with the presence of LGE. B. The corresponding differences between the late gadolinium enhance-
ment (LGE) extent in septal compared to the lateral myocardial segments in the respective patient groups. Boxes contain values between
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In  the  present  study,  using  state  of  the  art  CMR  imag-
ng,  we  showed  that  septal  myocardial  segments  revealed  a
igniﬁcantly  higher  LGE  extent  than  lateral  myocardial  seg-
ents  in  the  whole  group  of  patients  with  HCM  as  well  as  in
he  subgroups  of  patients  with  HOCM  and  those  with  LGE.
n  contrast  to  these  ﬁndings,  in  the  subgroup  of  patients
ith  HNCM  and/or  in  those  HCM  patients  without  the  pres-
nce  of  LGE,  septal  and  lateral  MAPSE  were  comparably
educed.  Although  the  total  amount  of  LGE  was  signiﬁcantly
reater  in  HNCM  patients  than  in  patients  with  HOCM,  the
istribution  pattern  of  LGE  was  different.  HNCM  patients
evealed  a  more  ‘balanced’  LGE,  being  more  equally  dis-
ributed  to  the  septal  and  lateral  myocardial  segments,
xplaining  the  analogous  reduction  of  septal  and  lateral
APSE  in  these  patients.  Furthermore,  reduced  MAPSE  mea-
urements  showed  a  signiﬁcant  inverse  correlation  with  the
GE  extent.  This  fact  could  suggest  a  possible  link  between
educed  MAPSE  measurements,  ﬁbrotic  tissue  and  longitudi-
al  dysfunction.
During  the  5.1-year  follow-up,  six  patients  (6.8%)  suf-
ered  from  MACE  and  10  patients  (11.4%)  suffered  from
troke.  We  found  that,  in  patients  suffering  from  MACE  or
troke,  MAPSE  was  signiﬁcantly  reduced  and  the  amount  of
GE  was  signiﬁcantly  greater  compared  to  patients  without
C
O
Mreline indicates the median. Vertical lines represent the lower and
vents.  These  results  are  in  line  with  previous  studies
27—30],  highlighting  the  clinical  importance  of  LGE  as  an
ndependent  risk  factor  for  predicting  sudden  cardiac  death
nd  adverse  outcomes  in  patients  with  HCM.  Reduced  MAPSE
as  proven  to  be  a  risk  factor  for  MACE  in  patients  with  heart
ailure  due  to  ischaemic  heart  disease  and  atrial  ﬁbrillation
31—33]  as  well  as  in  critically  ill  patients  with  shock  [34].
he  results  of  our  present  study  suggest  that  a  reduced  sep-
al  MAPSE  might  also  have  prognostic  implication  in  patients
ith  HCM.
imitations
hen  determining  MAPSE,  one  has  to  keep  in  mind  that
he  differences  between  healthy  controls  and  patients  are
mall,  requiring  accurate  measurements.  However,  CMR
ssessment  allows  the  exact  delineation  of  points  and
etection  of  even  small  differences  thus  facilitating  this
hallenge.linical implication
ne  could  assume  that  due  to  the  correlation  between
APSE  and  LGE  extent,  a  marked  increase  of  LGE  could
[[
[
[
[
[
[
[MAPSE  for  ﬁbrosis  detection  in  HCM  
result  in  a  further  reduction  of  MAPSE.  Furthermore,  the
measurement  of  MAPSE  only  requires  the  acquisition  of  a
four-chamber  cine  view,  which  is  always  obtained  in  clinical
routine.  No  speciﬁc  sequences  or  post-processing  software
are  needed  for  analysis.  Therefore,  MAPSE  is  easy  to  obtain
and  could  be  used  as  a  reproducible,  longitudinal  monitoring
tool  for  LGE  changes  and  might  also  predict  an  unfavourable
prognosis.  However,  further  longitudinal  studies  are  needed
to  prove  this  hypothesis.
Conclusions
MAPSE  measurement  using  CMR  is  feasible,  reproducible  and
comparable  to  echocardiography  in  healthy  controls  and
patients  with  HCM.  In  patients  with  HCM,  all  MAPSE  mea-
surements  were  signiﬁcantly  reduced  compared  to  those
measurements  in  healthy  subjects.  In  healthy  controls,  val-
ues  for  septal  and  lateral  MAPSE  were  comparable.  This
ﬁnding  did  not  hold  true  for  patients  with  HCM.  In  line
with  a  more  pronounced  LGE  amount  in  the  septal  myocar-
dial  segments,  the  whole  group  of  HCM  patients,  as  well
as  the  subgroup  of  patients  with  HOCM  and  all  patients
with  HCM  and  evidence  of  LGE,  revealed  a  signiﬁcant  reduc-
tion  of  septal  compared  to  lateral  MAPSE.  The  subgroup  of
patients  with  HNCM  revealed  a  more  balanced  distribution
of  LGE  in  the  septal  and  lateral  myocardial  segments  along
with  a  more  comparable  reduction  of  septal  and  lateral
MAPSE.  Furthermore,  septal  and  lateral  MAPSE  were  simi-
lar  in  patients  with  HCM  without  LGE.  Therefore,  reduced
MAPSE  seems  to  be  an  easy  determinable  surrogate  marker
of  ﬁbrosis  leading  to  left  ventricular  mechanical  dysfunc-
tion  in  patients  with  HCM.  MAPSE  measurement  might  serve
as  an  easily  measurable,  reproducible,  longitudinal  monitor-
ing  tool  for  ﬁbrotic  changes  in  these  patients.  Moreover,  in
patients  with  HCM  suffering  from  MACE  or  stroke,  MAPSE  was
signiﬁcantly  reduced  and  the  amount  of  LGE  was  signiﬁcantly
greater  compared  to  patients  without  events.  These  results
suggest  that  a  reduced  MAPSE  might  also  have  a  prognostic
implication.
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